Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.

Autor:	Gasoyan H; Department of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, OH.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH., Anwer F; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Casacchia NJ; Department of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, OH., Kovach JD; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH., Valent J; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH., Wang M; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH., Halpern MT; Healthcare Delivery Research Program, National Cancer Institute, Bethesda, MD., Rothberg MB; Department of Internal Medicine and Geriatrics, Center for Value-Based Care Research, Primary Care Institute, Cleveland Clinic, Cleveland, OH.; Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH.
Jazyk:	angličtina
Zdroj:	JCO oncology practice [JCO Oncol Pract] 2024 May; Vol. 20 (5), pp. 699-707. Date of Electronic Publication: 2024 Feb 14.
DOI:	10.1200/OP.23.00672
Abstrakt:	Purpose: Little is known about the role of social determinants of health (SDOH) in the utilization of novel treatments among patients with newly diagnosed multiple myeloma (NDMM). Methods: This retrospective cohort study used Taussig Cancer Center's Myeloma Patient Registry to identify adults with NDMM between January 1, 2017, and December 31, 2021. Electronic health records data captured treatment with (1) triplet or quadruplet regimen and (2) lenalidomide during the first year after NDMM, and (3) stem-cell transplant (SCT) through December 31, 2022. Multivariable logistic regression models examined associations of demographic/clinical characteristics and SDOH with care patterns. Results: We identified 569 patients with median age at diagnosis of 66 years (IQR, 59-73); 55% were male, 76% White, 23% Black, 1.1% other races, insured by Medicare (51%), private payer (38%), Medicaid (8.3%), and self-pay/other (1.8%). In the multivariable models, self-pay/other payers (adjusted odds ratio [AOR], 0.15 [95% CI, 0.03 to 0.54]) was associated with lower odds of triplet or quadruplet regimen, compared with Medicare. Private insurance (AOR, 0.48 [95% CI, 0.27 to 0.86]) and self-pay/other payers (AOR, 0.16 [95% CI, 0.04 to 0.74]) had lower odds of lenalidomide. Black patients ( v White; AOR, 0.47 [95% CI, 0.26 to 0.85]) and patients treated at regional hospitals ( v Taussig Cancer Center; AOR, 0.27 [95% CI, 0.12 to 0.57]) had lower odds of SCT. The odds of receiving triplet or quadruplet regimen, lenalidomide, and SCT also varied by the year of NDMM. Conclusion: Care for NDMM varied based on race, insurance type, year of diagnosis, and treatment facility. It may be useful to examine the impact of insurance-related characteristics and recent policy initiatives on care disparities.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu